Jimandin

Sitagliptin, the active ingredient in Jimandin, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is used to improve blood‑glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jimandin belongs to the DPP‑4 inhibitor class and is indicated for managing hyperglycaemia in type 2 diabetes.

Type 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise. Adjunct therapy with metformin: provides additional HbA1c reduction in patients inadequately controlled on metformin alone.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Nausea: occasional feeling of stomach upset. - Diarrhoea: loose stools occurring intermittently. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with possible vomiting, requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Hepatic injury: elevated liver enzymes indicating possible liver stress. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Bullous pemphigoid: rare skin blistering disorder.

Patients should be evaluated for renal function before initiating therapy and monitored periodically.

Renal function assessment: adjust dose or avoid use in severe impairment. Monitor for pancreatitis: discontinue if severe abdominal pain occurs. Caution in heart failure: assess fluid status regularly. Avoid in known hypersensitivity: discontinue if allergic reaction develops. Use with caution in hepatic impairment: monitor liver enzymes. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin): reduce sitagliptin effectiveness. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: potential dehydration may affect glucose control. - ACE inhibitors: monitor blood pressure and renal function. - Warfarin: possible alteration of INR values. - NSAIDs: increased risk of renal impairment when combined.